To inform estimations of the potential impact of recently introduced pneumococcal conjugate vaccine (PCV), we report results of 11 years of pre-PCV surveillance for invasive pneumococcal disease (IPD) among children in Guatemala City. Methods: Cases of IPD in children younger than 5 years were identified by active surveillance at 3 referral hospitals in Guatemala City from October 1996 through 2007. Clinical and demographic data were obtained, and isolates of Streptococcus pneumoniae from normally sterile sites were serotyped using latex agglutination and confirmed by Quellung reaction. Results: Four hundred fifty-two cases of IPD were identified with a case fatality rate of 21%. Meningitis was the most common cause of death (77% of all deaths) and occurred more often in infancy (median age 5 months) than other clinical syndromes. Of the 137 isolates serotyped, type 1 (26 cases, 17%), type 2 (25 cases, 16%) and type 5 (18 cases, 12%) were the most common. Serotype 2 was associated with a higher case fatality rate (28%), higher rate of meningitis (68%) and occurred in younger infants (median age, 3.5 months) than other common serotypes. Recently introduced PCV13 includes 73% of observed serotypes in the study. Conclusion: Infants with IPD presented at a young age. Serotype 2, rarely reported as a significant cause of IPD and not included in available PCVs, was a common cause of disease in this population. PCV13 introduction in Guatemala, begun in 2013, may not have as great an impact in disease reduction as has been observed in other countries.
S
treptococcus pneumoniae is the most important cause of meningitis, bacterial pneumonia and bacteremia in children. 1 Though significant reductions in invasive pneumococcal disease (IPD) have been achieved in many high-income nations after introduction of pneumococcal polysaccharide conjugate vaccines (PCVs), IPD remains a major cause of global pediatric and adult morbidity and mortality in many countries. 2, 3 In the past decade, low-income and middle-income countries (LMICs) have increasingly incorporated PCVs into their routine immunization schedules. 4, 5 However, the serotypes causing pediatric IPD and the potential impact of PCV introduction will vary by region and country. 5, 6 Because pneumococcal conjugate vaccines are more expensive than most vaccines in use in LMICs, an accurate determination of the potential benefit of PCV introduction is useful for stakeholders considering PCV introduction. In addition, understanding local pneumococcal epidemiology could allow consideration of optimal PCV schedules for a given population and anticipation of what resources will need to be committed to monitoring IPD after PCV introduction.
In 2013, the Guatemalan national immunization program added PCV13 to the routine immunization schedule. We report results from 11 years of pre-PCV surveillance for IPD in children younger than 5 years from tertiary hospitals in Guatemala City, with a focus on pneumococcal serotype distribution and their clinical disease spectrum. Our results highlight potential limitations for vaccine efficacy in countries like Guatemala and the importance of assessing local pneumococcal epidemiology in LMIC before PCV introduction.
METHODS
Children younger than 60 months hospitalized at 3 major referral hospitals (Roosevelt Hospital, Hospital San Juan de Dios and the Hospital General del Instituto Guatemalteco de Seguridad Social) serving primarily urban, low-income public sector patients in Guatemala City from October 1996 through December 2007 were part of a longitudinal surveillance program to detect pediatric invasive bacterial infection as described previously (Fig. 1) . 7 Though PCVs have been licensed in Guatemala since 2005, pneumococcal vaccine was not available for children served by the public system during the study period. All admissions were screened by study staff and enrolled in the surveillance study if signs or symptoms suggestive of invasive bacterial infection were present at or shortly after hospitalization. Children suspected of having meningitis routinely underwent lumbar puncture for diagnosis before initiation of hospital-based therapy. In children with severe illness or suspected of having sepsis, physicians commonly obtained blood cultures. Chest radiogram were performed in children suspected of having pneumonia. When appropriate, samples of sterile fluids (pleural, joint, etc.) were obtained by attending physicians. A standardized form was used for all cases of invasive bacterial disease to record basic demographic and clinical information from patient charts. A case of IPD in the surveillance cohort was defined as severe illness (defined below) associated with identification of pneumococcus from blood or normally sterile sites. cerebrospinal fluid (CSF) pleocytosis (≥10 wbc/μL) with a positive blood or distant sterile site culture. Sepsis was defined as bacteremia with signs of systemic infection and no evidence of focal infection. Pneumonia was defined as clinical and radiographic signs of lower respiratory tract infection and identification of pneumococcus in blood and/or pleural fluid by culture and/or latex agglutination. Other localized infections (arthritis, orbital cellulitis, arthritis, etc.) were defined as identification of pneumococcus in blood or tissue culture associated with evidence of focal infection.
Blood cultures were performed using the Bactec automated system at all hospitals (Becton-Dickinson, Baltimore, MD). Samples from fluids (CSF, pleural or other sterile fluids) were inoculated onto blood and chocolate agar plates and incubated at 34-35°C in 5% CO 2 for 48 hours. Colonies with alpha-hemolysis were evaluated for morphology, Gram staining and optochin-disk susceptibility. Slide latex agglutination kits for S. pneumoniae identification were used for CSF, pleural fluid, blood and other sterile fluids (Becton-Dickinson, Baltimore, MD). Serotyping was performed on culture-positive specimens using specific standard antiserum by the Quellung reaction (Statens Serum Institute, Copenhagen, Denmark). Not all cultures were recoverable after storage at the time serotyping was undertaken, and thus, only a subset (all recovered cultures) of the total initially positive cultures was serotyped.
Data were entered using EpiInfo (Centers for Diseases Control and Prevention, Atlanta, GA) analyzed using STATA, Version 11.0 (College Station, TX). Comparisons of demographic characteristics, clinical outcomes and mortality were done using Z tests, Wilcoxon rank-sum tests, χ 2 or Fisher exact tests where appropriate. Statistical significance was defined as a P value <0.05.
This observational study was approved as exempt by the institutional review boards at the Johns Hopkins Bloomberg School of Public Health (Baltimore, MD) and the San Juan de Dios and Roosevelt Hospitals Research and Ethics Committees (Guatemala City, Guatemala).
RESULTS
Of the 4643 cases of suspected invasive bacterial infection identified during the surveillance period, 452 (9.7%) met the criteria for IPD. Demographic and clinical characteristics of cases are presented in Table 1 . No association of disease with season or yearto-year trends in incidence or mortality were noted. The median age at presentation was 11.3 months. There was a predominance of males (57%, P = 0.002, large sample Z test).
Ninety-seven children with IPD died for a case fatality rate (CFR) of 21.5%. Meningitis and pneumonia constituted 81% of all cases. Meningitis had the highest CFR (38%) and was responsible for 76% of all deaths, followed by sepsis (CFR, 23.8%; 20% of all deaths). Pneumonia was an infrequent cause of mortality, resulting in only 4 deaths and a CFR of 2%. One case of orbital cellulitis and no bone or joint infections were identified. The overall CFR was highest (31.3%) in infants younger than 1 year, compared with 13.4% for children aged 1-3, and 9.8% for 3-5 years old (P < 0.001, χ 2 test). The majority of meningitis cases (78%) occurred in children younger than 12 months with a median age of 5 months (Fig. 2) . Notably, 37% of meningitis cases occurred before 4 months of age-the planned timing of the second dose of PCV for Guatemalan children-and 56% occurred before 6 months of age.
Pneumococcal serotypes were identified for 137 (30.3%) of the total 452 IPD cases, and 19 further samples were identifiable to the level of serogroup, but not serotype. The most common serotypes causing IPD were type 1 (26 cases, 17%), type 2 (25 cases, 16%), type 5 (18 cases, 12%), type 14 (13 cases, 8%) and type 6A (12 cases, 8%). There were 16 cases of serogroup 19 isolated, out of which 7 could be serotyped. Five of those 7 were identified as 19F. Similarly, 9 serogroup 23 samples were 23F, with an additional 4 unable to be serotyped.
Serotype 2 was the second most common serotype identified and was associated with the highest number of deaths and meningitis cases (17 cases, 68% of all type 2 cases; Table 2 ). The 3 most common serotypes (1, 2 and 5) were less frequently associated with sepsis than the remaining serotypes combined (9% vs. 26%, P = 0.006, Fisher exact test), and types 1 and 5 were associated with significantly higher rates of pneumonia (63% vs. 27%, P < 0.001, χ 2 test). Types 1, 2 and 5 caused 93% (14/15) of all pneumonias with pleural effusion (Fig. 3 ). There were no statistically significant differences in overall mortality rate between serotype although the overall numbers of deaths for each serotype were small. Serotype 2 caused disease at a younger age than other serotypes on aggregate (median age, 3.5 vs. 11.7 months, P = 0.002, Wilcoxon rank-sum test).
Of the 137 identified serotypes, 100 (73%) are included in PCV13 and 84 (61%) in PCV10. Potential PCV coverage was 62% (PCV13) and 52% (PCV10) for serotypes causing meningitis, 75% and 58% for sepsis, and 84% and 74% for severe pneumonia. Vaccine coverage for serotypes causing death in our study was 72% for PCV13 and 61% for PCV10. The 2 additional serotypes in the proposed PCV15 (22F and 33F) would not add any additional coverage based on our results in this population.
DISCUSSION
These data provide important information about prominent serotypes causing IPD, serotype coverage from PCV13 and factors related to age and disease severity that will influence the potential impact of the recent PCV13 introduction in Guatemala. Serotype 2, although uncommon in most other populations, caused a high proportion of IPD and deaths in our study. A recent report of IPD in Bangladesh revealed a similar high incidence of severe disease caused by serotype 2. 8 Reports of serotype 2 as a significant pneumococcal pathogen date back to the first half of the 20th century, including a description of 1000 adult cases in 1932. 9 However, heterogeneity within the original serotyping (initially notated as serotype "II") may limit extrapolation to currently characterized serotype 2. In early descriptions, serotype 2 was an uncommon cause of pediatric disease, representing only 6 (1.8%) of 329 childhood pneumonia cases in 1931.
10 A 7-decade review of serotypes causing IPD in children from 1938 to 2007 in Denmark demonstrated that serotype 2 disappeared as a pathogen by the 1970s, perhaps in response to increasing use of antibiotics after the 1940s. 11 Whether our findings (and those from Bangladesh) represent an emergence of a novel virulent serotype 2 or a distinct micro-ecological niche is unclear. In the Bangladeshi series, disease associated with serotype 2 pneumococcus was overwhelmingly meningitis (98%). The high proportion (68%) of meningitis in children with serotype 2 IPD in our series and the low prevalence in nasopharyngeal colonization studies suggest this serotype as is a highly invasive strain. Furthermore, identification of serotype 2 in 2 children with complicated pneumonia with pleural effusion suggests this is an invasive type in pulmonary infections, similar to that of serotypes 1 and 5. [12] [13] [14] Our data also provide evidence regarding the potential impact of the recently introduced PCV13 for prevention of pneumococcal disease in Guatemala. PCV13 covers only 73% of serotypes identified in our study population referred to these public hospitals. Before the introduction of PCV7 in the US, the 7 serotypes in the original PCV accounted for approximately 80% of isolates from blood and CSF in children <6 years of age in the US. 5 A subsequent increase in the non-PCV7 serotypes, especially 19A, after PCV7 introduction in the shifted the effectiveness calculus, but introduction of PCV13 overcame this problem. 15, 16 The estimated serotype coverage and vaccine effectiveness for LMIC are variable.
6,17-21 Our findings support the need for local IPD surveillance to evaluate the impact of PCV introduction and to identify subsequent emergence and replacement by nonvaccine serotypes. The young age of presentation of IPD provides useful data for the selection of the immunization schedules in LMICs. The pre-PCV7 epidemiologic data in the US found the highest incidence of pediatric IPD in infants between 6 and 12 months, optimal timing for a vaccination schedule with completed 3-dose primary series by 6 months of age. 5 In Guatemala, the majority of meningitis cases (56%) and deaths (56%) occurred before 6 months of age, consistent with other LMIC populations. 22 Because protection from PCVs may not be achieved until after the second vaccine dose, many infants in this age range will depend on indirect protection that will only be attained by reaching a high level of population immunity in older children. Therefore, in populations where the distribution of IPD is skewed toward younger infants, PCV schedules that include a booster dose or add catch up campaigns for pre-school children may witness a faster and higher impact on IPD incidence. 23 In the US, before PCV7 introduction, only 14% of nonoccult bacteremia IPDs resulted in meningitis. 5 In Guatemala, we found a high proportion of IPD was meningitis (43%), and the mortality rate from meningitis in our population (38%) was 4-5 times those reported in the US, likely attributable to delays in seeking care and more limited resources. 14, 24, 25 A previous study also identified concurrent pneumonia and sepsis as risk factors for all-cause meningitis mortality in this same population, highlighting the severity of disease at presentation. 26 Thus, the positive impact of PCV13 introduction on mortality in Guatemalan infants is likely to be more pronounced than in many higher income nations.
The use of a hospital-based surveillance limits the extrapolation of our findings to the burden of all pneumococcal disease in the community, especially pneumonia. This is perhaps compounded by potential use of antibiotic among patients before admission, as disease caused by more drug susceptible or less aggressive serotypes is more likely to have been cured in the community. 7, 27 On the other hand, this population represents the most significant morbidity and mortality burden from IPD and therefore a best-case scenario of the potential impact of vaccine on severe disease. Additional limitations include the serotyping of only 30% of the isolates from children with IPD because some pneumococcal strains were lost during storage. The effect of prior antibiotic therapy decreasing isolation in some cases may also have skewed the serotype representation in our study.
In conclusion, this study describes a high proportion of IPD caused by serotypes 2, 1 and 5; PCV serotype coverage of 73% and a high burden of illness in young children with a high CFR. These findings emphasize the importance of active surveillance preintroduction and postintroduction of pneumococcal vaccination in LMICs.
